Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled SNG001 in Hospitalised Patients with Moderate COVID-19
NCT04732949Phase 3Completed
- Sponsor
- Synairgen
- Start
- Jan 2021
- Primary completion
- Dec 2021
- Modality
- Cytokines & Interferons
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing SNG001 with Placebo (2 arms). Primary endpoints: Time to Hospital Discharge at Day 28 and Time to Recovery at Day 28. Started Jan 2021; status: completed.
02
Drugs
interferon beta-1a
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04732949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04732949.